Microsoft Ventures, the VC arm of Microsoft Microsoft has now invested in DNAnexus, a leading biomedical informatics and data management startup. The DNAnexus platform powers genomics by allowing organizations to address these challenges:
- Analyze massive volumes of raw sequencing data quickly, securely, and economically;
- Integrate genomic data with clinical and other phenotypic data in a secure and compliant environment;
- Collaborate seamlessly and safely.
Interestingly, GV (formerly Google Ventures) has also invested in this startup. DNAnexus will use this equity investment to support its expansion in the clinical trials market as well as the deployment of the company’s pioneering Translational Informatics Suite for pharmaceutical and other research organizations.
“The financing enables further development and the launch of our translational medicine solutions, as well as expanding our footprint in cloud-based management of genomic data in clinical trials,” said Richard Daly, Chief Executive Officer of DNAnexus. “The next wave of biomedical insights is coming from cross-institutional collaborations that produce rapidly increasing amounts of multi-omics data. We are proud of our work dedicated to improving how global research and development organizations leverage large biomedical datasets to develop and deliver precision medicine solutions.”
Learn more about DNAnexus here.